AI precision medicine · genomic data OS
Tempus AI
An AI precision-medicine company that uses oncology genetic testing as a data-acquisition funnel to build one of the world's largest multimodal medical datasets and sells that data back to pharma. Of 2025 revenue of $1.27B (+83%), Diagnostics (genetic testing) is 75% ($955M) and funds the model, while Data & Apps at 25% ($316M) is the high-margin leg — it buys Illumina sequencing and NVIDIA compute to create data and sell it to pharma. The re-rating axis is whether data-to-pharma monetization (e.g., the $200M oncology foundation model with AstraZeneca and Pathos) scales faster than the capital-intensive diagnostics leg.
TEM Updated Jul 12, 2026 3 AI consumers· 1 recurring
Per the valuechain.wiki graph, Tempus AI is directly linked to 2 companies (2 supply, 0 revenue relationships) and reaches 3 companies within two hops; the links are backed by 3 dated sources, 1 of them primary filings (as of 2026-07-12).
Financials & Segments
- Total revenue · 2025 revenue $1.27B (+83%)
- Customer concentration · AstraZeneca/Pathos $200M; diagnostics $955M.
- Segments · Diagnostics 75% · Data & Apps 25%
Revenue from
- Hospitals · diagnostics (oncology genetic testing) High confidence
Oncology DNA/RNA and liquid-biopsy testing to hospitals (75% of revenue). - Pharma (AZ · Pathos data · foundation models) High confidence
Data licensing and foundation-model fees ($200M) to pharma like AstraZeneca and Pathos.Confirms EN Yahoo Finance Published Jan 1, 2026: Tempus diagnostics and data arms drive growth (AZ foundation model)
Pays to
- Illumina Medium confidence
Depends on Illumina and others for sequencing, the starting cost of genetic testing — the key upstream input that powers the diagnostics data-funnel (75% of revenue), so sequencing unit cost drives the segment's margin. - NVIDIA Medium confidence
Depends on NVIDIA for the compute to train foundation models — the upstream cost of building the 'model' it sells to pharma, where compute spend scales with the growing dataset.Confirms EN Yahoo Finance Published Jan 1, 2026: Tempus diagnostics and data arms drive growth (AZ foundation model) - Cloud · labs (undisclosed) Low confidence
Cloud and lab operations.
Value-chain ripple (2 tiers)
Following node-to-node links up to 2 tiers; each firm is shown once, at its nearest tier.
| Company | Chain | '21 | '22 | '23 | '24 | '25 | YTD |
|---|---|---|---|---|---|---|---|
| Tempus AI | node | · | · | · | · | +74.9 | -1.4 |
| Illumina | benef1 | +2.8 | -46.9 | -31.1 | -1.3 | -1.8 | +45 |
| NVIDIA | benef2 | +125.5 | -50.3 | +239 | +171.2 | +38.9 | +13.3 |
| Amazon | benef2 | +2.4 | -49.6 | +80.9 | +44.4 | +5.2 | +6.3 |
YTD as of 2026-07-10 · source: Yahoo Finance
Tempus's thesis is a flywheel — collect data through diagnostics, sell it to pharma. Diagnostics (75% of revenue, $955M) matters less for its own profit than as the funnel that accumulates multimodal data, while Data & Apps (25%, $316M) is the high-margin monetization leg — the $200M foundation-model deal with AstraZeneca and Pathos is the proof of that shift. In the graph this node buys Illumina (sequencing) and NVIDIA (compute) upstream and sells hospital testing and pharma data licenses downstream. The question is whether +83% revenue growth scales the data leg past the capital intensity of diagnostics; the risks are compute/sequencing cost and the pace of data monetization.
Analysis generated from returns as of 2026-07-09Analyst ratings
Consensus: Buy 2 · Hold 1 · Sell 0 · Avg. target $70 · Price $58.23 (07-10) · Upside +20%
Analyses covering this node
- The application is still a story, the infrastructure demand is already measured: techbio as the first case Jun 23, 2026